Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate

Company to initiate Phase 1 of the first-ever clinical trial for KIR-CAR T cells in Q1 2023 PHILADELPHIA, Sept. 20, 2022 /PRNewswire/ — Verismo Therapeutics, a clinical-stage biotechnology company and a Penn-spinout behind the novel KIR-CAR platform technology, today announced that is…

About the Author

has written 37398 stories on this site.

Copyright © 2010 Business and Corporate News.